Literature DB >> 25806161

Status quo and prospects of the translational research on lung cancer in China.

Ping Zhan1, Yong Song2.   

Abstract

Entities:  

Year:  2012        PMID： 25806161      PMCID： PMC4367592          DOI： 10.3978/j.issn.2218-6751.2011.12.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  10 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Medicine. The NIH Roadmap.

Authors:  Elias Zerhouni
Journal:  Science       Date:  2003-10-03       Impact factor: 47.728

3.  Bench to bedside: the glutamate connection.

Authors:  D W Choi
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

4.  From bench to bedside.

Authors:  Karen Kreeger
Journal:  Nature       Date:  2003-08-28       Impact factor: 49.962

5.  Translational research: the full cycle.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2008-06-12       Impact factor: 49.962

6.  Adenomatous polyposis coli and translational medicine.

Authors:  J Geraghty
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

7.  A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese.

Authors:  Zhibin Hu; Chen Wu; Yongyong Shi; Huan Guo; Xueying Zhao; Zhihua Yin; Lei Yang; Juncheng Dai; Lingmin Hu; Wen Tan; Zhiqiang Li; Qifei Deng; Jiucun Wang; Wei Wu; Guangfu Jin; Yue Jiang; Dianke Yu; Guoquan Zhou; Hongyan Chen; Peng Guan; Yijiang Chen; Yongqian Shu; Lin Xu; Xiangyang Liu; Li Liu; Ping Xu; Baohui Han; Chunxue Bai; Yuxia Zhao; Haibo Zhang; Ying Yan; Hongxia Ma; Jiaping Chen; Mingjie Chu; Feng Lu; Zhengdong Zhang; Feng Chen; Xinru Wang; Li Jin; Jiachun Lu; Baosen Zhou; Daru Lu; Tangchun Wu; Dongxin Lin; Hongbing Shen
Journal:  Nat Genet       Date:  2011-07-03       Impact factor: 38.330

8.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

9.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.